Abstract
Background: Paclitaxel (Taxol®) is a novel chemotherapeutic agent, active against a variety of tumors. It is not known whether the drug penetrates brain tumor tissue. Patients and methods: Three patients with a recurrent glioma received paclitaxel (175 mg/m2) in a 3-hour i.v. infusion prior to surgery. Paclitaxel concentrations were measured in the tumor tissue, cerebrospinal fluid, cyst fluid, plasma and, in one patient, normal brain tissue. Results: Tumor tissue concentrations were in the thera- peutic range in all three patients. Brain tissue concentration, however, was below the detection limit of the trial. Conclusions: These findings suggest that paclitaxel may have a place in brain tumor therapy. The low concentration in normal brain tissue, as observed in one patient, may suggest, however, that the drug does not cross the intact blood-brain barrier. © 1994 Kluwer Academic Publishers.
Author supplied keywords
Cite
CITATION STYLE
Heimans, J. J., Vermorken, J. B., Wolbers, J. G., Eeltink, C. M., Meijer, O. W. M., Taphoorn, M. J. B., & Beijnen, J. H. (1994). Paclitaxel (TAXOL®) concentrations in brain tumor tissue. Annals of Oncology, 5(10), 951–953. https://doi.org/10.1093/oxfordjournals.annonc.a058736
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.